Market Analysis

Anxiety disorders drug market likely to decrease from $4.5 billion to $2.6 billion by 2015

Published in Health and Medicine Week, May 18th, 2006

The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 primarily due to the launch of numerous generic anxiety drugs from 2006 onwards.

The influx of generic anxiety drugs will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs, according to a research report, "Anxiety Disorders - A Decade of Declining Revenues," released by Research and Markets.

The reported includes an analysis for key products in development for GAD (generalized anxiety disorder), SAD (social anxiety disorder), OCD (obsessive-compulsive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2006-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry